Wikipedia -WSS

Wikipedia

author：fashion 2025-10-01 10:36:11 - browse：83628

Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Readout Newsletter: CAR

WSS

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

In the gardens at Boston Children's Hospital, families find sanctuary

Steward Health Care Massachusetts hospitals face fiscal disaster

The haunting brain science of long Covid

STAT Report: Patient voices and perspectives

Readout Newsletter: CAR

focus

Wikipedia

knowledge

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Moonlake's readout produced a cash windfall. Risks remain

EPA limits use of carcinogenic gas for sterilizing medical devices

The high cost of giving birth even with insurance

A new crop of companies is reshaping the health data economy

Guidelines to prevent youth baseball injuries need more muscle

First U.S. drug developed to treat liver disease MASH is approved

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Bristol, Sangamo, Gilead, and more

focus

UHS says company favors patients whose insurance pays more

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

New lawsuit accuses health insurer Cigna of denying claims in bulk

UHS says company favors patients whose insurance pays more

Roche’s Alnylam deal shows drug firms interested in heart drugs

focus

knowledge

explore

entertainment